Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2012

View Archived Issues

Chugai recaps development activities of third quarter 2012

First-in-class protein kinase inhibitor evaluated in Japanese patients with solid tumors

Phase I trial results reported for novel vaccine for glioblastoma

Cellectis obtains exclusive license for genome engineering tools

Shire and Fondazione Telethon enter research collaboration for rare diseases

ALX-009 reduces P. aeruginosa biofilm formation

Data presented from phase II study of pazopanib in NETs

Data for phase II TemAvir study in patients with glioblastoma presented

Elara Pharmaceuticals discloses novel HIF-1-alpha inhibitors

Atlanthera discloses new agents for cancer and other disorders

IMPACT Therapeutics patents new PARP-1 inhibitors

Japanese group patents novel anticancer CDC7 inhibitors

New double-stranded RNA molecules disclosed for the treatment of cancer

ADX-71441 shows promise in preclinical model of alcohol binge drinking

Teijin Pharma to begin phase I/II trial of KTP-001

ViaCyte receives grant to continue development of diabetes therapy

Salivary miRNAs identified as potential noninvasive diagnostic method in esophageal cancer

Shionogi and ViiV Healthcare form new integrase inhibitor agreement

E.U. approval for linagliptin as add-on therapy in type 2 diabetes

Phase III enobosarm trial to continue after planned safety review

Evotec extends Huntington's disease collaboration

Isis begins phase II study of ISIS-FXIRx in knee replacement surgery

Novel TNFR-Fc fusion protein shows promise in animal models of Alzheimer's disease

Application for additional approval for Lucentis filed in Japan

Second-generation aminoglycoside derivative leads dose-dependent rescue of CFTR currents in vitro

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...